Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 35 | 2023 | 20824 | 1.990 |
Why?
|
Radiation Oncology | 11 | 2023 | 555 | 1.910 |
Why?
|
Breast Implantation | 6 | 2022 | 218 | 1.230 |
Why?
|
Mammaplasty | 5 | 2022 | 1204 | 1.210 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 11 | 2022 | 1624 | 1.040 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2021 | 806 | 0.960 |
Why?
|
Breast Implants | 3 | 2022 | 387 | 0.930 |
Why?
|
Mastectomy | 11 | 2022 | 1793 | 0.830 |
Why?
|
Radiotherapy Dosage | 10 | 2022 | 2879 | 0.780 |
Why?
|
Thoracic Wall | 3 | 2018 | 203 | 0.690 |
Why?
|
Breast Neoplasms, Male | 1 | 2021 | 210 | 0.680 |
Why?
|
Tattooing | 1 | 2019 | 58 | 0.660 |
Why?
|
Sarcopenia | 1 | 2023 | 368 | 0.630 |
Why?
|
Radiation Injuries | 3 | 2022 | 1180 | 0.630 |
Why?
|
Curriculum | 9 | 2022 | 3605 | 0.600 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2018 | 137 | 0.590 |
Why?
|
Medical Oncology | 4 | 2022 | 2267 | 0.560 |
Why?
|
Mastectomy, Segmental | 3 | 2021 | 956 | 0.550 |
Why?
|
Benchmarking | 1 | 2022 | 1042 | 0.530 |
Why?
|
Organs at Risk | 4 | 2022 | 346 | 0.530 |
Why?
|
Mediastinal Neoplasms | 1 | 2018 | 423 | 0.510 |
Why?
|
Breast | 4 | 2021 | 1970 | 0.480 |
Why?
|
Women's Health | 1 | 2022 | 2034 | 0.430 |
Why?
|
Protons | 4 | 2022 | 1127 | 0.430 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2013 | 140 | 0.420 |
Why?
|
Pituitary Neoplasms | 1 | 2021 | 1345 | 0.420 |
Why?
|
Neoplasms, Second Primary | 1 | 2020 | 1062 | 0.420 |
Why?
|
Supratentorial Neoplasms | 1 | 2013 | 160 | 0.410 |
Why?
|
Heart | 3 | 2022 | 4464 | 0.400 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2022 | 2073 | 0.390 |
Why?
|
Radiobiology | 2 | 2020 | 85 | 0.340 |
Why?
|
Lymphoma | 1 | 2018 | 1877 | 0.330 |
Why?
|
Internship and Residency | 4 | 2023 | 5791 | 0.320 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2023 | 3480 | 0.320 |
Why?
|
Cerebellar Neoplasms | 1 | 2013 | 587 | 0.310 |
Why?
|
Lymph Nodes | 1 | 2019 | 3476 | 0.310 |
Why?
|
Medulloblastoma | 1 | 2013 | 683 | 0.310 |
Why?
|
Photons | 4 | 2019 | 588 | 0.300 |
Why?
|
Female | 43 | 2023 | 380193 | 0.280 |
Why?
|
Humans | 64 | 2023 | 744366 | 0.270 |
Why?
|
Clinical Clerkship | 3 | 2015 | 532 | 0.250 |
Why?
|
Neoplasms | 6 | 2023 | 21696 | 0.250 |
Why?
|
Cultural Diversity | 2 | 2023 | 359 | 0.240 |
Why?
|
Radiotherapy, Conformal | 3 | 2018 | 548 | 0.240 |
Why?
|
Patient Participation | 1 | 2013 | 1457 | 0.230 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2023 | 9240 | 0.230 |
Why?
|
Seroma | 1 | 2022 | 71 | 0.210 |
Why?
|
Hypertension | 1 | 2022 | 8479 | 0.210 |
Why?
|
Program Evaluation | 4 | 2020 | 2488 | 0.210 |
Why?
|
Family Leave | 1 | 2021 | 18 | 0.200 |
Why?
|
Supreme Court Decisions | 1 | 2022 | 128 | 0.190 |
Why?
|
Education, Nursing | 1 | 2021 | 82 | 0.190 |
Why?
|
Relative Biological Effectiveness | 2 | 2021 | 323 | 0.180 |
Why?
|
Sick Leave | 1 | 2021 | 110 | 0.180 |
Why?
|
Clinical Trials as Topic | 3 | 2023 | 7914 | 0.180 |
Why?
|
Accreditation | 1 | 2023 | 452 | 0.180 |
Why?
|
Students, Medical | 4 | 2021 | 1862 | 0.180 |
Why?
|
Physics | 1 | 2019 | 87 | 0.170 |
Why?
|
Cranial Irradiation | 2 | 2013 | 401 | 0.170 |
Why?
|
Thorax | 1 | 2022 | 547 | 0.170 |
Why?
|
Retrospective Studies | 13 | 2023 | 77460 | 0.170 |
Why?
|
Rib Fractures | 1 | 2020 | 131 | 0.160 |
Why?
|
Troponin | 1 | 2022 | 524 | 0.160 |
Why?
|
Education, Medical, Graduate | 2 | 2023 | 2291 | 0.160 |
Why?
|
Canada | 2 | 2022 | 2065 | 0.160 |
Why?
|
Craniopharyngioma | 1 | 2021 | 281 | 0.160 |
Why?
|
Necrosis | 1 | 2022 | 1643 | 0.160 |
Why?
|
Moyamoya Disease | 1 | 2021 | 238 | 0.160 |
Why?
|
Nausea | 1 | 2021 | 674 | 0.160 |
Why?
|
Lymphatic Metastasis | 2 | 2018 | 2924 | 0.150 |
Why?
|
Vomiting | 1 | 2021 | 637 | 0.150 |
Why?
|
Safety | 1 | 2022 | 1186 | 0.150 |
Why?
|
Hematoma | 1 | 2022 | 758 | 0.150 |
Why?
|
Policy | 1 | 2021 | 508 | 0.150 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2019 | 358 | 0.140 |
Why?
|
Radiation Tolerance | 1 | 2019 | 486 | 0.140 |
Why?
|
Congresses as Topic | 1 | 2020 | 764 | 0.140 |
Why?
|
Patient Care Planning | 1 | 2021 | 921 | 0.130 |
Why?
|
Physician-Patient Relations | 3 | 2021 | 3229 | 0.130 |
Why?
|
Treatment Outcome | 11 | 2023 | 63107 | 0.130 |
Why?
|
Aged | 14 | 2023 | 163288 | 0.130 |
Why?
|
Patient Positioning | 1 | 2018 | 324 | 0.130 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 551 | 0.130 |
Why?
|
Tumor Burden | 1 | 2021 | 1915 | 0.130 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2023 | 1524 | 0.130 |
Why?
|
Cisplatin | 1 | 2021 | 1662 | 0.120 |
Why?
|
Postoperative Care | 2 | 2018 | 1487 | 0.120 |
Why?
|
Postoperative Complications | 3 | 2022 | 15297 | 0.120 |
Why?
|
Pulmonary Fibrosis | 1 | 2018 | 530 | 0.120 |
Why?
|
Vision Disorders | 1 | 2021 | 1058 | 0.120 |
Why?
|
Fatigue | 1 | 2021 | 1531 | 0.110 |
Why?
|
Disease-Free Survival | 2 | 2021 | 6896 | 0.110 |
Why?
|
Propensity Score | 1 | 2020 | 1781 | 0.110 |
Why?
|
Middle Aged | 18 | 2023 | 213390 | 0.110 |
Why?
|
Small Molecule Libraries | 1 | 2019 | 720 | 0.110 |
Why?
|
Headache | 1 | 2021 | 1226 | 0.110 |
Why?
|
Quality of Life | 5 | 2022 | 12802 | 0.110 |
Why?
|
Ventricular Function, Left | 2 | 2022 | 3666 | 0.100 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1410 | 0.100 |
Why?
|
Stroke Volume | 2 | 2022 | 5006 | 0.100 |
Why?
|
Needs Assessment | 1 | 2018 | 1147 | 0.100 |
Why?
|
Acculturation | 1 | 2013 | 182 | 0.100 |
Why?
|
Surgical Flaps | 1 | 2020 | 1640 | 0.100 |
Why?
|
Adult | 16 | 2023 | 214052 | 0.100 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1692 | 0.100 |
Why?
|
Terminal Care | 2 | 2013 | 1694 | 0.100 |
Why?
|
Schizophrenia, Paranoid | 1 | 2011 | 104 | 0.100 |
Why?
|
Endocrine System Diseases | 1 | 2013 | 248 | 0.100 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2020 | 1004 | 0.100 |
Why?
|
Attitude to Death | 1 | 2013 | 382 | 0.090 |
Why?
|
Terminally Ill | 1 | 2013 | 238 | 0.090 |
Why?
|
Ambulatory Care | 1 | 2021 | 2708 | 0.090 |
Why?
|
Bone Density Conservation Agents | 1 | 2017 | 772 | 0.090 |
Why?
|
Massachusetts | 2 | 2021 | 8662 | 0.090 |
Why?
|
Peptide Fragments | 1 | 2022 | 5096 | 0.090 |
Why?
|
Echocardiography | 1 | 2022 | 5099 | 0.090 |
Why?
|
Pectoralis Muscles | 2 | 2020 | 82 | 0.090 |
Why?
|
Prospective Studies | 6 | 2022 | 53290 | 0.090 |
Why?
|
Feedback | 3 | 2021 | 795 | 0.090 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2020 | 1771 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11525 | 0.080 |
Why?
|
Interviews as Topic | 2 | 2013 | 2539 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2019 | 5077 | 0.080 |
Why?
|
United States | 7 | 2022 | 69872 | 0.080 |
Why?
|
Patient Preference | 2 | 2013 | 889 | 0.080 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2417 | 0.080 |
Why?
|
Young Adult | 5 | 2023 | 56429 | 0.080 |
Why?
|
Male | 12 | 2023 | 350115 | 0.080 |
Why?
|
Career Choice | 1 | 2014 | 744 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6539 | 0.070 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2013 | 770 | 0.070 |
Why?
|
Radiology | 1 | 2021 | 2099 | 0.070 |
Why?
|
Genomics | 1 | 2023 | 5717 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2022 | 39052 | 0.070 |
Why?
|
Body Height | 1 | 2013 | 1578 | 0.070 |
Why?
|
Education, Medical, Undergraduate | 1 | 2015 | 1008 | 0.070 |
Why?
|
Cultural Competency | 1 | 2009 | 289 | 0.070 |
Why?
|
Hospice Care | 1 | 2013 | 672 | 0.070 |
Why?
|
Survival Rate | 2 | 2018 | 12788 | 0.070 |
Why?
|
Infant | 2 | 2021 | 35134 | 0.070 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 25039 | 0.060 |
Why?
|
Bone Neoplasms | 1 | 2017 | 2530 | 0.060 |
Why?
|
Child, Preschool | 2 | 2021 | 41005 | 0.060 |
Why?
|
Neoplasm Staging | 4 | 2021 | 11031 | 0.060 |
Why?
|
Radiosurgery | 1 | 2014 | 1329 | 0.060 |
Why?
|
Mass Screening | 1 | 2020 | 5253 | 0.060 |
Why?
|
Neoadjuvant Therapy | 3 | 2020 | 2727 | 0.060 |
Why?
|
Cause of Death | 1 | 2013 | 3582 | 0.050 |
Why?
|
Lung | 2 | 2018 | 9857 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2023 | 57776 | 0.050 |
Why?
|
Brain Neoplasms | 2 | 2014 | 8861 | 0.050 |
Why?
|
Consensus | 2 | 2021 | 2960 | 0.050 |
Why?
|
Linear Energy Transfer | 1 | 2021 | 154 | 0.050 |
Why?
|
Governing Board | 1 | 2019 | 53 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2021 | 892 | 0.040 |
Why?
|
Administrative Personnel | 1 | 2019 | 187 | 0.040 |
Why?
|
Program Development | 2 | 2015 | 1316 | 0.040 |
Why?
|
Logistic Models | 1 | 2013 | 13409 | 0.040 |
Why?
|
Surgical Mesh | 1 | 2020 | 276 | 0.040 |
Why?
|
Pandemics | 3 | 2022 | 8385 | 0.040 |
Why?
|
Radiology, Interventional | 1 | 2021 | 460 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2022 | 1680 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2013 | 13991 | 0.040 |
Why?
|
Cost Allocation | 1 | 2016 | 51 | 0.030 |
Why?
|
Lung Neoplasms | 2 | 2019 | 13104 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2019 | 730 | 0.030 |
Why?
|
Certification | 1 | 2019 | 423 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2020 | 1590 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2021 | 5388 | 0.030 |
Why?
|
Fluorouracil | 1 | 2020 | 1619 | 0.030 |
Why?
|
Educational Measurement | 2 | 2015 | 1210 | 0.030 |
Why?
|
Phenylurea Compounds | 1 | 2019 | 528 | 0.030 |
Why?
|
Models, Econometric | 1 | 2016 | 218 | 0.030 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2019 | 651 | 0.030 |
Why?
|
Organ Specificity | 1 | 2020 | 2008 | 0.030 |
Why?
|
Monte Carlo Method | 1 | 2020 | 1254 | 0.030 |
Why?
|
Prognosis | 3 | 2023 | 29060 | 0.030 |
Why?
|
Device Removal | 1 | 2020 | 656 | 0.030 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2019 | 594 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2017 | 841 | 0.030 |
Why?
|
Chicago | 1 | 2014 | 240 | 0.030 |
Why?
|
Child | 1 | 2021 | 77709 | 0.030 |
Why?
|
Diphosphonates | 1 | 2017 | 623 | 0.030 |
Why?
|
Pyrazines | 1 | 2019 | 1230 | 0.030 |
Why?
|
Adolescent | 1 | 2021 | 85779 | 0.030 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2020 | 948 | 0.030 |
Why?
|
Markov Chains | 1 | 2016 | 969 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2019 | 9955 | 0.030 |
Why?
|
Advance Directives | 1 | 2013 | 246 | 0.030 |
Why?
|
Fear | 1 | 2020 | 1440 | 0.020 |
Why?
|
Imidazoles | 1 | 2017 | 1206 | 0.020 |
Why?
|
Social Support | 1 | 2020 | 2118 | 0.020 |
Why?
|
Catheterization | 1 | 2016 | 1470 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 20130 | 0.020 |
Why?
|
Clinical Competence | 2 | 2018 | 4687 | 0.020 |
Why?
|
Reoperation | 1 | 2020 | 4201 | 0.020 |
Why?
|
Age Factors | 2 | 2017 | 18373 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2016 | 1683 | 0.020 |
Why?
|
Retreatment | 1 | 2011 | 610 | 0.020 |
Why?
|
Life Expectancy | 1 | 2016 | 1184 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2460 | 0.020 |
Why?
|
Delusions | 1 | 2011 | 300 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2014 | 1180 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8642 | 0.020 |
Why?
|
Cell Survival | 1 | 2019 | 5882 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2023 | 12356 | 0.020 |
Why?
|
Communication | 1 | 2022 | 3750 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4216 | 0.020 |
Why?
|
Radiometry | 1 | 2013 | 800 | 0.020 |
Why?
|
Societies, Medical | 1 | 2019 | 3743 | 0.020 |
Why?
|
Hospitals, General | 1 | 2011 | 749 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6755 | 0.020 |
Why?
|
Decision Support Systems, Clinical | 1 | 2016 | 1164 | 0.020 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2011 | 388 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2020 | 12244 | 0.020 |
Why?
|
Animals | 1 | 2018 | 168768 | 0.020 |
Why?
|
Faculty | 1 | 2009 | 387 | 0.020 |
Why?
|
Steroids | 1 | 2011 | 930 | 0.020 |
Why?
|
Problem-Based Learning | 1 | 2009 | 361 | 0.020 |
Why?
|
Internet | 1 | 2018 | 3056 | 0.020 |
Why?
|
Recurrence | 1 | 2017 | 8340 | 0.020 |
Why?
|
Remission Induction | 1 | 2011 | 2385 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2013 | 2453 | 0.020 |
Why?
|
Risk Factors | 3 | 2020 | 72296 | 0.020 |
Why?
|
Pilot Projects | 1 | 2018 | 8319 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2017 | 3817 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2760 | 0.020 |
Why?
|
HIV Infections | 1 | 2011 | 16715 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10252 | 0.020 |
Why?
|
Dexamethasone | 1 | 2011 | 1951 | 0.010 |
Why?
|
Mutation | 2 | 2019 | 29786 | 0.010 |
Why?
|
Time Factors | 2 | 2018 | 40075 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10483 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2013 | 2575 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 16690 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8091 | 0.010 |
Why?
|
Caregivers | 1 | 2013 | 2095 | 0.010 |
Why?
|
Coronary Disease | 1 | 2016 | 6077 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9312 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14723 | 0.010 |
Why?
|
Radiography | 1 | 2011 | 7023 | 0.010 |
Why?
|
Palliative Care | 1 | 2011 | 3493 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 19905 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13286 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 5223 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2011 | 6773 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 35425 | 0.000 |
Why?
|
Concepts
(249)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(98)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_